Stock Analysis

Avinger Full Year 2022 Earnings: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Source: Shutterstock

Avinger (NASDAQ:AVGR) Full Year 2022 Results

Key Financial Results

  • Revenue: US$8.27m (down 18% from FY 2021).
  • Net loss: US$27.2m (loss widened by 26% from FY 2021).
  • US$4.36 loss per share.
NasdaqCM:AVGR Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Avinger shares are down 5.8% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Avinger that you should be aware of.

What are the risks and opportunities for Avinger?

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally.

View Full Analysis


  • Has less than 1 year of cash runway

  • Shareholders have been substantially diluted in the past year

  • Does not have a meaningful market cap ($7M)

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report